OT mobile menu

Search form


Gastrointestinal Cancer Targets

New Targeted Agent, IMMU-130, Could Treat Colon Cancer

New data suggests that an experimental targeted therapy known as IMMU-130 may be effective in controlling drug-resistant metastatic colorectal cancer in patients previously treated with irinotecan-containing chemotherapy regimens. Image © Shutterstock.com

Gastrointestinal Cancer Targets

We spoke with Dr. Luis Diaz about his recent presentation on immunotherapy in colorectal cancer at the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held January 19–21 in San Francisco.

In my practice, I am constantly being asked how to properly treat scalp involvement in relation to these skin toxicities.

New data are suggesting that deciphering the genomic diversity and evolution of tumors may provide a basis for identifying new targets and designing improved personalized medicine strategies.

The Pancreatic Cancer Action Network is aiming to improve the lives of patients diagnosed with the third-leading cause of cancer-related death with a new precision drug trial.

If you’ve been in oncology long enough, you’ve likely seen the patient who presents with metastatic disease, gets first-line therapy, progresses, switches to second-line therapy, progresses again, and so on, with their cancer becoming increasingly more resistant to therapy.

Circulating tumor DNA detected after resection of stage II colon cancer appears to identify patients who are at high-risk of tumor recurrence.

Researchers are reporting they have identified ERCC3 as a new target for pancreatic cancer and demonstrated the effects are extremely strong in a molecularly defined subset of patients.


Subscribe to Gastrointestinal Cancer Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.